沈阳皮肤科七院就诊时间(沈阳市治疗皮肤瘙痒的好医院) (今日更新中)

When a rumor of a mass shooting trickled out late Wednesday evening, play director Brett Elliott was putting the finishing touches on a student production.“Immediately people started panicking and crying, not knowing who to reach out to first because all of their friends could have been there,” Elliott describes.Elliott was set to direct a play about the Columbine High School shooting with student actors at California Lutheran University. The play “Columbinus” was based on the events that took place in the 1999 shooting in Columbine, Colorado.“I was sitting right over here to your right, giving final notes and instructions to my actors, literally on how to effectively portray people affected by a mass shooting, Elliott says.“We thought it was vital three days ago. We thought it was immediate three days ago. Now, it’s on our doorstep.”One of his cast members did, in fact, lose a best friend.“I've spent a month and half with these kids, trying to teach them what it could be like to experience an event like this, try to help them get into the minds of people, of a community affected by an event like this,” Elliott says. “I would never in a million years have wished for them to actually live it. It’s heartbreaking.”This weekend's opening performances have been canceled. The future of the production is unclear.However, Elliott and the cast unanimously agree that it should go on."It is exponentially more important to us all now," Elliott says.Whether the play will go on is up to the university. But if theatre's job is to hold a mirror up to nature, to society, Elliott believes the show must go on, especially now.“This show is why we do theatre,” Elliott says. “This show is why theatre exists.” 1724

White House chief of staff John Kelly announced at a senior staff meeting Monday that President Donald Trump asked him to stay on as chief of staff until at least 2020 -- and that he agreed -- three White House officials confirmed to CNN.The news came after Kelly marked his first anniversary as chief of staff amid a swirl of rumors about his potentially imminent departure. The Wall Street Journal first reported news of Kelly's plans.Kelly has seen his status as chief of staff diminished in recent months, with the President circumventing many of the policies and protocols the retired Marine Corps general put in place when he entered the West Wing last year.In the two weeks leading up to Trump's disruptive swing through Europe, senior aides predicted that Kelly had days or hours left. Those same aides now think the ensuing chaos of the trip may have helped Kelly hang on a little longer.The-CNN-Wire 917

When President-Elect Joe Biden and Vice President-Elect Kamala Harris take office in January, they will face a list of extraordinary challenges. The coronavirus pandemic and America's response to it will loom large. The same week our country voted for president, there were record numbers of new COVID-19 cases and hospitalizations and deaths continue to rise. Vaccines are being developed and could be ready for widespread distribution next year. There is also the financial and jobs concerns in the wake of the pandemic. Many are hoping conversations about economic relief can start up again now that results of the election are becoming clear. The jobs report from October shows unemployment is at 6.9 percent. However, this is still historically high and there are concerns it does not include people who have given up looking for work during a pandemic for various reasons.Racism and social justice issues divided the country earlier this year, leading to large demonstrations in dozens of cities. Strong emotions from both sides motivated some voters. Biden has said he also wants to focus on rejoining international organizations, including the World Health Organization, NATO, and the Paris Climate Accord. Biden has also signaled other top priorities in his first few months; including sending a bill to Congress to repeal liability protections for gun manufacturers and closing background-check loopholes, sending an immigration bill to Congress creating a pathway to citizenship for 11 million undocumented immigrants and retaining rights for “dreamers” who were brought to the United States illegally as children, and move to eliminate tax cuts passed under Trump in 2017, according to the Washington Post. In speeches, Biden has also said he wants to address systemic racism, homelessness, and restore transgender students' access to sports, bathrooms and locker rooms. 1891

With a coronavirus vaccine still months off, companies are rushing to test what may be the next best thing: drugs that deliver antibodies to fight the virus right away, without having to train the immune system to make them.Antibodies are proteins the body makes when an infection occurs; they attach to a virus and help it be eliminated. Vaccines work by tricking the body into thinking there’s an infection so it makes antibodies and remembers how to do that if the real bug turns up.But it can take a month or two after vaccination or infection for the most effective antibodies to form. The experimental drugs shortcut that process by giving concentrated versions of specific ones that worked best against the coronavirus in lab and animal tests.“A vaccine takes time to work, to force the development of antibodies. But when you give an antibody, you get immediate protection,” said University of North Carolina virologist Dr. Myron Cohen. “If we can generate them in large concentrations, in big vats in an antibody factory ... we can kind of bypass the immune system.”These drugs are believed to last for a month or more and could give quick, temporary immunity to people at high risk of infection, such as health workers and housemates of someone with COVID-19. If they proved effective and if a vaccine doesn’t materialize or protect as hoped, the drugs might eventually be considered for wider use, perhaps for teachers or other groups.They’re also being tested as treatments, to help the immune system and prevent severe symptoms or death.“The hope there is to target people who are in the first week of their illness and that we can treat them with the antibody and prevent them from getting sick,” said Dr. Marshall Lyon, an infectious disease specialist helping to test one such drug at Emory University in Atlanta.Having such a tool “would be a really momentous thing in our fight against COVID,” Cohen said.Vaccines are seen as a key to controlling the virus, which has been confirmed to have infected more than 20 million people worldwide and killed more than 738,000. Several companies are racing to develop vaccines, but the results of the large final tests needed to evaluate them are months away.The antibody drugs are “very promising” and, in contrast, could be available “fairly soon,” said Dr. Janet Woodcock, a U.S. Food and Drug Administration official who is leading government efforts to speed COVID-19 therapies. Key studies are underway and some answers should come by early fall.One company, Eli Lilly, has already started manufacturing its antibody drug, betting that studies now underway will give positive results.“Our goal is to get something out as soon as possible” and to have hundreds of thousands of doses ready by fall, said Lilly’s chief scientific officer, Dr. Daniel Skovronsky.Another company that developed an antibody drug cocktail against Ebola — Regeneron Pharmaceuticals Inc. — now is testing one for coronavirus.“The success with our Ebola program gives us some confidence that we can potentially do this again,” said Christos Kyratsous, a Regeneron microbiologist who helped lead that work.Regeneron’s drug uses two antibodies to enhance chances the drug will work even if the virus evolves to evade action by one.Lilly is testing two different, single-antibody drugs — one with the Canadian company AbCellera and another with a Chinese company, Junshi Biosciences. In July, Junshi said no safety concerns emerged in 40 healthy people who tried it and that larger studies were getting underway.Others working on antibody drugs include Amgen and Adaptive Biotechnologies. The Singapore biotech company Tychan Pte Ltd. also is testing an antibody drug and has similar products in development for Zika virus and yellow fever.“I’m cautiously optimistic” about the drugs, said the nation’s top infectious diseases expert, Dr. Anthony Fauci. “I’m heartened by the experience that we had with Ebola,” where the drugs proved effective.What could go wrong?— The antibodies may not reach all of the places in the body where they need to act, such as deep in the lungs. All the antibody drugs are given through an IV and must make their way through the bloodstream to wherever they’re needed.— The virus might mutate to avoid the antibody — the reason Regeneron is testing a two-antibody combo that binds to the virus in different places to help prevent its escape.Skovronsky said Lilly stuck with one antibody because manufacturing capacity would essentially be cut in half to make two, and “you will have less doses available.” If a single antibody works, “we can treat twice as many people,” he said.— The antibodies might not last long enough. If they fade within a month, it’s still OK for treatment since COVID-19 illness usually resolves in that time. But for prevention, it may not be practical to give infusions more often than every month or two.A San Francisco company, Vir Biotechnology Inc., says it has engineered antibodies to last longer than they usually do to avoid this problem. GlaxoSmithKline has invested 0 million in Vir to test them.Giving a higher dose also may help. If half of antibodies disappear after a month, “if you give twice as much, you will have two months’ protection,” Lilly’s Skovronsky said.— The big fear: Antibodies may do the opposite of what’s hoped and actually enhance the virus’s ability to get into cells or stimulate the immune system in a way that makes people sicker. It’s a theoretical concern that hasn’t been seen in testing so far, but large, definitive experiments are needed to prove safety.“As best as we can tell, the antibodies are helpful,” Lyon said.___Marilynn Marchione can be followed on Twitter: @MMarchioneAP___The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content. 5919

With Democrats set to take control of the House in January, speculation abounds about whether the new majority would impeach the President.Americans break against that idea, according to a new CNN poll conducted by SSRS. Half, 50%, say they don't feel that Trump ought to be impeached and removed from office, while 43% say he should be. Support for impeachment has dipped some since September, when 47% favored it, and is about the same as in a June poll (42% favored it then). Support for impeachment of Trump remains higher than it was for each of the last three presidents at any time it was asked. It's on par with President Richard Nixon, who 43% of Americans said should be impeached and removed from office in a March 1974 Harris poll.The shift on impeachment comes mostly from political independents. In September, they were evenly split on the question, with 48% behind impeachment and 47% opposed. Now, 36% favor impeachment and 55% are opposed.There's also been a meaningful shift on the question among younger adults (53% of those under age 45 backed impeachment in September, now that's down to 45%) and racial and ethnic minorities (66% favored it in September, 50% do now).Related: Full poll resultsTrump himself warned his supporters during the 2016 midterm campaign that Democrats would try to impeach him, although Democratic leaders like soon-to-be House Speaker Nancy Pelsoi have dismissed the idea.More recently, Trump has been worrying about the prospect, according to reporting by CNN's Jim Acosta, as a number of his former associates cooperate with the special counsel investigation into possible collusion by Trump's campaign with Russians interfering in the 2016 election.The incoming Democratic chairman of the House Judiciary Committee, Jerry Nadler of New York, told CNN's Jake Tapper that if allegations by Michael Cohen that Trump directed him to issue illegal payments to women alleging affairs to keep them quiet during the 2016 election were true, those would constitute "impeachable offenses." At the same time, Nadler made no suggestion Democrats would pursue impeachment against Trump.One reason Democrats might not impeach Trump even if he is ultimately implicated by special counsel Robert Mueller is that while they control the House, and so could potentially impeach him in that chamber with a simple majority, Republicans will still control of the US Senate. It would require the defection of 20 Republican senators to remove Trump from office if he were impeached by Democrats in the House.That defection among the President's partisans failed to happened when Republicans in the House impeached Bill Clinton in the late 1990s. There were nowhere near the 67 votes needed in the Senate to remove Clinton from office.Trump, however, is not nearly as popular now as Clinton was then. Clinton reached more than 70% approval when the House voted to impeach him in December of 1998, according to CNN/Gallup/USA Today polling.Former President Richard Nixon, who resigned rather than be impeached, had a much lower approval rating than Trump has now. He was under 30% approval when he resigned in August of 1974. Trump's approval rating has remained remarkably steady, in the high 30s and low 40s -- much less than Clinton, but much higher than Nixon.All of this remains academic since Democratic leaders have not expressed any interest in impeaching Trump.The CNN Poll was conducted by SSRS December 6 through 9 among a random national sample of 1,015 adults reached on landlines or cellphones by a live interviewer. Results for the full sample have a margin of sampling error of plus or minus 3.8 percentage points, it is larger for subgroups. 3691

来源：资阳报